ArticleScientific reports2026
Mechanism of AGEs-RAGE axis inhibition of ferroptosis in type 2 diabetic colon cancer by regulatory CEACAM1.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) patients with colon cancer have an increased incidence and poor prognosis, which may be closely related to advanced glycation end products (AGEs) and its receptor (RAGE), but the underlying mechanism is still unclear. The aim of this study is to investigate how the AGEs-RAGE axis inhibits ferroptosis in T2DM-associated colon cancer by regulating carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). ELISA and Western blot were used to detect expression levels of CEACAM1 in 155 patients with colon cancer. In vitro experiments examined various parameters in CEACAM1 knockdown/overexpression cells co-cultured with AGEs. The molecular mechanism was validated using multiple detection methods following intervention with FPS-ZM1 and sabatolimab. Serum and tissue analyses revealed that CEACAM1 is up-regulated in colon cancer patients with T2DM. The AGEs-RAGE promotes colon cancer cell proliferation, migration and invasion by upregulating CEACAM1. CEACAM1 overexpression triggers IFN-γ pathway, thereby enhancing SLC7A11/GPX4-mediated ferroptosis resistance. Blockade of RAGE with FPS-ZM1 reverses CEACAM1 driven inhibition of ferroptosis by reducing GPX4. A nude mouse model of type 2 diabetic tumors was established to assess tumor growth. Furthermore, blockade of Tim-3 by sabatolimab disrupts its interaction with CEACAM1, restoring ferroptosis sensitivity and inhibiting subcutaneous tumor growth in these mice. The AGEs-RAGE axis inhibits ferroptosis by driving CEACAM1 overexpression and mediating IFN-γ/SLC7A11/GPX4 signaling pathway, which reveals a new mechanism by which AGEs-RAGE-CEACAM1 promotes tumor survival in diabetic environment. Sabatolimab may provide a therapeutic strategy for colon cancer patients with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.